



# Isolation, Identification and Antibiotic Sensitivity Pattern of *Salmonella typhi* Isolated from Blood Samples of Patients in Dhaka City, Bangladesh

Mohammad Mizanur Rahman<sup>1</sup>, Maruf Abony<sup>1</sup>, Kaniz Fatema<sup>1</sup>, Suvamoy Datta<sup>1\*</sup>

## Abstract

In recent years, there has been a significant rise in the prevalence of multidrug resistance *Salmonella typhi* in Dhaka city. To study the prevalence rate and identification of typhoidal *Salmonella typhi* among the patients attending at a hospital by conventional test. It was seen that 88% (Amoxyclave) of the *S. typhi* strains are resistant to the antibiotics used against them. Gentamycin, Levofloxacin and Meropenem (100% sensitive) are the best drugs for the treatment of *S. typhi* infection followed by Ciprofloxacin (99% sensitive). None of the samples exhibited sensitivity to more than four drugs. Typhoid fever occurs infrequently in developed countries but massively in developing countries. Traditionally the drugs of choice were chloramphenicol, ampicillin, and cotrimoxazole but unfortunately the emergence of multidrug resistant strains of *S. typhi* introduced the use of Amikacin, Imipenem & Netilmycin among the patients. However, now a day's ciprofloxacin used frequently as a drug of choice but this study, isolated *S. typhi* are sensitive to ciprofloxacin 95 % that twisted the circumstances into different directions.

**Significance** | The study highlights rising multidrug-resistant *Salmonella typhi* in Dhaka, emphasizing effective antibiotic choices crucial for managing prevalent typhoid fever in developing regions.

\*Correspondence. Suvamoy Datta, Department of Microbiology, Primeasia University, Dhaka, Bangladesh.  
E-mail: suvamoy.datta@primeasia.edu.bd

Editor Abu Zafur Ziuddin Ahmed, And accepted by the Editorial Board Dec 15, 2020 (received for review Oct 11, 2020)

**Keywords:** Salmonella, Blood Samples, Antibiotic Sensitivity, Bangladesh.

## Introduction

Worldwide, typhoid fever affects roughly 17 million people annually, causing nearly 216,000 deaths (WHO 2007). This disease is rare in developed countries, but it continues to be a major health problem and poses the risk of emergence due to poor hygienic and sanitary conditions prevalent in developing countries (Crump et al. 2004; Crump & Mintz 2010). The causative agent, *Salmonella enterica* serovar Typhi, is an obligate parasite that has no known natural reservoir outside of humans (Parry et al. 2002). The increasing multi-drug resistance (MDR) of this organism is causing additional problems in the treatment and management of typhoid fever (Le Hello et al. 2011). The emergence of *Salmonella Typhi* strains resistant to multiple antibiotics has been causing enormous childhood morbidity and increasing the cost of therapy (Rowe et al. 1997). *Salmonella Typhi* and *Salmonella Paratyphi A* belong to the family Enterobacteriaceae. They are Gram-negative, rod-shaped, non-spore-forming, motile (with peritrichous flagella), facultative anaerobic organisms (Brenner et al. 2000). *Salmonella* lives in the intestinal tracts of warm and cold-blooded animals. Some species are ubiquitous, while other species are specifically adapted to a particular host (Bäumler et al. 1998). In humans, *Salmonella* cause two diseases called salmonellosis: enteric fever (typhoid), resulting from bacterial invasion of the bloodstream, and acute gastroenteritis, resulting from a foodborne infection/intoxication

## Author Affiliation.

<sup>1</sup> Department of Microbiology, Primeasia University, Dhaka, Bangladesh.

## Please cite this article.

Mohammad Mizanur Rahman, Maruf Abony, Kaniz Fatema, Suvamoy Datta, (2020). Isolation, Identification and Antibiotic Sensitivity Pattern of *Salmonella typhi*/Isolated from Blood Samples of Patients in Dhaka City, Bangladesh. Journal of Primeasia, 1(1), 1-5, 560014

(Glynn et al. 1998). Until 1990, there was no evidence of clinically important MDR strains of *S. Typhi* in Bangladesh, and typhoid fever was treated with the first-line antibiotics like ampicillin, chloramphenicol, co-trimoxazole, and some third-generation cephalosporins and quinolones, which were most effective for the treatment of Salmonella infections (Rahman et al. 1997). But in early 1990, MDR *S. Typhi* was detected in the clinical microbiology laboratory of ICDDR, B, and since then it has been isolated at an increasing frequency (Rahman et al. 1997). A study conducted at the Dhaka treatment centre of ICDDR, B showed that the frequency of MDR strains increased from 8% in 1990 to 51% in 1994 (Rahman et al. 1997). However, in the succeeding two years, the frequency of resistance to these drugs decreased to 24-31% (Rahman et al. 1997). Hereafter, it has been found that resistance to multidrug further increased from 31% in 1997 to 40% in 2001 (Saha et al. 2001). The development of antimicrobial resistance among Salmonella isolates in Bangladesh has created a new problem for the management of this illness (Saha et al. 2001). Until 1989, the treatment of typhoid fever was relatively simple in Bangladesh, like in many other countries, since all *S. Typhi* isolates were uniformly susceptible to first-line antibiotics, i.e., ampicillin, chloramphenicol, and co-trimoxazole (Rowe et al. 1997). Although a few sporadic cases of typhoid fever caused by antibiotic-resistant *S. Typhi* were reported, there was no evidence of clinically important resistance among the strains of *S. Typhi* in Bangladesh before 1990. In the early 1990s, multidrug-resistant *S. Typhi* strain was detected in the clinical microbiology laboratory of ICDDR, B, and since then it has been isolated at an increasing frequency (Rahman et al. 1997). The frequency of MDR in this case increased from 8% in 1990 to 51% in 1994 (Rahman et al. 1997).

## Materials and Methods

### Clinical Specimens

The clinical specimens used in this study were blood samples collected from typhoid patients who attended Medinova Medical Service LTD, Dhaka during January to June 2018. Blood samples were collected using sterile syringe and aseptic conditions were maintained in all cases. Blood Samples were collected using BD Vacutainer® Blood collection Needle made in USA and aseptic conditions were maintained in all cases.

Isolation of Salmonella spp. Blood samples were inoculated directly onto MacConkey's and Salmonella-Shigella agar plates. The plates were then incubated overnight at 37°C and examined for non-lactose fermenting pale colonies. All the cultures were inoculated under aseptic conditions. Growth of microorganisms on solid media was carried out in agar plates in incubators (Eyela Incubator, Japan; member Cool Incubator, Germany).

### Identification of Salmonella spp.

#### Biochemical tests

The isolated Salmonella spp. was further confirmed by biochemical tests following the standard procedures describe [2]. The isolates were also streaked on MacConkey's agar plate & Shigella Salmonella agar plate. The pure bacterial cultures were routinely maintained on MacConkey's Agar, Salmonella Shigella Agar plates. The cultures were stored at 4-8°C until required. The stock cultures were stored at -20°C and at -70°C.

#### Serological tests

Serological study was performed by a slide agglutination test. Dry and clean glass slide was marked into several parts with a wax pencil. A drop of normal saline was placed on each block. An isolated colony of Salmonella species was touched with a sterile loop and suspended in normal saline. Commercially available Salmonella antisera were added to the suspension. After back-and-forth movement of the slide for two minutes, agglutination was observed against diffuse light. Serotyping was done using specific antisera.

#### Antibiogram

#### Determination of antimicrobial susceptibility by Kirby-Bauer method

Bacterial susceptibility to antimicrobial agents was determined by using the Kirby-Bauer [3] disc-diffusion method by using antibiotic containing disks from Oxoid Ltd, UK as well as the manufacturer instructions about the clear zones of growth inhibition around the disks.

## Results and Discussion

To study the prevalence of multidrug resistant *Salmonella typhi* in cases with typhoid fever, a total of 80 *Salmonella typhi* samples were tested in this study as shown in Table 1.

### Colony characteristics


The colonies of were moderately large, thick, moist circular disks, dome-shaped and smooth; the opacity and size varied with different strains. Color of the colonies were grayish white on SS agar and pale or colorless in MacConkey's medium.

### Biochemical characterization


The standard biochemical tests further confirmed the Salmonella isolates. All 120 isolates showed KIA (H<sub>2</sub>S production), Citrate utilization (-ve), MR (+ve), VP (-ve), Indole production (-ve), Catalase (+ve), and Oxidase (-ve), as shown in figure 1. The emergence of MDR *Salmonella typhi* (resistant to ampicillin, chloramphenicol and co-trimoxazole) initiated consistent use of fluoroquinolones that proven to be effective for the treatment of typhoid fever [4]. However, several failures of clinical treatment of typhoid patients with ciprofloxacin and other fluoroquinolones have been reported recently by [5] and some studies also confirmed the presence of fluoroquinolone resistant *S. typhi* [6, 7, 8]. This study has been conducted during January to June 2011 to observe the prevalence and antibiotic susceptibility pattern of *S. typhi*

**Table 1.** Result of biochemical tests.

KIA			Citrate utilization	MR	VP	Indole production	Catalase	Oxidase
Butt	Slant	H <sub>2</sub> S						
Acid	Alkaline	+ve or -ve	-ve	+ve	-ve	-ve	+ve	-ve



**Figure 1:** Percentage (%) sensitivity of *Salmonella typhi* to antibiotics.



**Figure 2:** Overall Sensitivity (%) of *S. typhi* to each antibiotic.

among children population in Dhaka city. Furthermore, phenotypic traits of *S. typhi* were investigated in relation to MDR and amoxicillin & ciprofloxacin resistance mechanisms were inspected as shown in figure 2.

Since the isolation and correct identification of *S. typhi* is crucial for the characterization purpose, the colonies having typical cultural characteristics were selected as presumptive *S. typhi*, which were then subjected to biochemical and serological tests for confirmation. It was seen that 88% (Amoxyclave) of the *S. typhi* strains are resistant to the antibiotics used against them. Gentamycin, Levofloxacin and Meropenem (100% sensitive) are the best drugs for the treatment of *S. typhi* infection followed by Ciprofloxacin (99% sensitive). None of the samples exhibited sensitivity to more than four drugs. Children under age of 5 have higher incident rate of typhoid fever and this study also found a higher rate of typhoid fever. The spread of antibiotic resistance genes is usually associated with either the clonal spread of an epidemic strain or through the independent acquisition of the resistant genes on plasmids, transposons and on integrons. Clonal relationship among the strains can be achieved by using different molecular techniques. Reproducibility, typeability, discriminatory power, ease of interpretation and ease of performance are the most important criteria to be treated as good typing system (Tasnim et al., 2018). The control of typhoid fever is dependent upon provision of safe drinking water, effective sewage disposal, immunization, and identification and appropriate treatment of both cases and carriers. The widespread and injudicious use of fluoroquinolone is probably responsible for this emergence and therefore, prudent use of this class of antibacterial, surveillance for antimicrobial resistance of *S. typhi* and monitoring of clinical response while treating patients with typhoid fever is essential (Walid et al., 2017). There is also an urgent need to reevaluate fluoroquinolones breakpoints for *S. typhi*. Until then, screening of *S. typhi* isolates for nalidixic acid resistance should be routinely performed to alert the physician about the possibility of failure of ciprofloxacin therapy in patients with typhoid fever (Nair et al., 2018). Present resistance patterns of *S. typhi* and their trends should also be monitored in other neighboring countries. Further, in countries where typhoid fever is endemic, such as Bangladesh, investigation and treatment of typhoid fever cases at private laboratories and home, respectively, are the rule rather than exception. Usually, the patients are only admitted to the hospitals in case of initial treatment failure or complications. Therefore, strains isolated only from hospital in-patients, as shown in previous report may demonstrate higher rate of resistance which does not reflect the real picture in endemic areas of the particular country or community.

If these strains are widespread, as expected, a randomized, controlled trial comparing oral azithromycin to third generation cephalosporin treatment of typhoid fever due to these strains with

reduced susceptibility to fluoroquinolones is needed to better inform choice of optimal treatment.

### Conclusion

Typhoid fever is increasingly rare in developed countries but remains widespread in developing nations. Traditionally, chloramphenicol, ampicillin, and cotrimoxazole were preferred treatments. However, the rise of multidrug-resistant *S. typhi* strains necessitated the use of Amikacin, Imipenem, and Netilmycin. Recently, ciprofloxacin has become a common choice due to its efficacy. A study revealed that 95% of isolated *S. typhi* strains are sensitive to ciprofloxacin, significantly influencing treatment strategies. This finding underscores the evolving landscape of typhoid management, reflecting the ongoing battle against antibiotic resistance.

### Author contributions

S.D., conceptualized and developed the methodology, M.M.R., prepared the original draft, M.A. and K.F., collected data and reviewed and edited the writing.

### Acknowledgment

The author thanks the Department of Microbiology, Primeasia University, Dhaka, Bangladesh.

### Competing financial interests

The authors have no conflict of interest.

### References

- Bauer A 1966: Antibiotic susceptibility testing by a standardized single disc method. *American Journal of clinical pathology* 45: 149-158.
- Bäumler, A. J., Hargis, B. M., & Tsolis, R. M. (2000). Trick or treat: Salmonella interactions with host macrophages. *Annual Review of Microbiology*, 54(1), 203-231.
- Bhutta, Z. A. (1996). Impact of age and drug resistance on mortality in typhoid fever. *Archives of Disease in Childhood*, 75(3), 214-217.
- Bhutta, Z. A., & Dewraj, H. L. (2006). Current concepts in the diagnosis and treatment of typhoid fever. *BMJ*, 333(7558), 78-82.
- Brenner, F. W., Villar, R. G., Angulo, F. J., Tauxe, R., & Swaminathan, B. (2000). Salmonella nomenclature. *Journal of Clinical Microbiology*, 38(7), 2465-2467.
- Cao X, Kneen R, Nguyen T, Truong D, White N, Parry C 1999: A comparative study of ofloxacin and cefixime for treatment of typhoid fever in children. The Dong Nai Pediatric Center Typhoid Study Group. *The Pediatric infectious disease journal* 18(3): 245-248.
- Cappuccino, J.G. and Sherman, N. 1996: *Microbiology a Laboratory Manual*. The Benjamin Cummings Publishing Co. Inc., San Francisco.
- Chau TT, Campbell JI, Galindo CM, Van Minh Hoang N, Diep TS, Nga TTT 2007: Antimicrobial drug resistance of Salmonella enterica serovar Typhi in Asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. *Antimicrobial agents and chemotherapy* 51(12): 4315-4323.

- Chitnis V, Chitnis D, Verma S, Hemvani N 1999: Multidrug-resistant *Salmonella typhi* in India. *The Lancet* 354(9177): 514-515.
- Crump, J. A., & Mintz, E. D. (2010). Global trends in typhoid and paratyphoid fever. *Clinical Infectious Diseases*, 50(2), 241-246.
- Crump, J. A., Luby, S. P., & Mintz, E. D. (2004). The global burden of typhoid fever. *Bulletin of the World Health Organization*, 82(5), 346-353.
- Eykyn S, Williams H 1987: Treatment of multi resistant *Salmonella typhi* with oral ciprofloxacin. *The Lancet* 330(8572): 1407-1408.
- Glynn, M. K., Bopp, C., Dewitt, W., Dabney, P., Mokhtar, M., & Angulo, F. J. (1998). Emergence of multidrug-resistant *Salmonella enterica* serotype Typhimurium DT104 infections in the United States. *New England Journal of Medicine*, 338(19), 1333-1338.
- Gupta, S. K., Medalla, F., Omondi, M. W., Stroika, S., Whichard, J. M., & Fields, P. I. (2008). Laboratory-based surveillance of paratyphoid fever in the United States: travel and domestic acquisition. *Clinical Infectious Diseases*, 46(11), 1656-1663.
- Kariuki, S., Gordon, M. A., Feasey, N., & Parry, C. M. (2015). Antimicrobial resistance and management of invasive *Salmonella* disease. *Vaccine*, 33, C21-C29
- Keddy, K. H., Sooka, A., Smith, A. M., Musekiwa, A., & Tau, N. P. (2015). Typhoid fever in South Africa in an endemic HIV setting. *PLoS One*, 10(12), e0145445.
- Le Hello, S., Hendriksen, R. S., Doublet, B., Fisher, I., Nielsen, E. M., Whichard, J. M., ... & Weill, F. X. (2011). International spread of an epidemic population of *Salmonella enterica* serotype Kentucky ST198 resistant to ciprofloxacin. *Journal of Infectious Diseases*, 204(5), 675-684.
- Mermin JH, Villar R, Carpenter J, Roberts L, Samariddin A, Gasanova L 1999: A massive epidemic of multidrug-resistant typhoid fever in Tajikistan associated with consumption of municipal water. *The Journal of infectious diseases* 179(6): 1416-1422.
- Ochiai, R. L., Acosta, C. J., Danovaro-Holliday, M. C., Baiqing, D., Bhattacharya, S. K., Agtini, M. D., ... & Clemens, J. D. (2008). A study of typhoid fever in five Asian countries: disease burden and implications for controls. *Bulletin of the World Health Organization*, 86, 260-268.
- Parry CM, Hoa NTT, Diep TS, Wain J, Chinh NT, Vinh H 1999: Value of a single-tube Widal test in diagnosis of typhoid fever in Vietnam. *Journal of Clinical Microbiology* 37(9): 2882-2886.
- Parry, C. M., Hien, T. T., Dougan, G., White, N. J., & Farrar, J. J. (2002). Typhoid fever. *New England Journal of Medicine*, 347(22), 1770-1782.
- Rahman, M., Siddique, A. K., Tam, F. C., & Nishibuchi, M. (1997). Emergence of multidrug-resistant *Salmonella Typhi* in Bangladesh. *Journal of Medical Microbiology*, 46(8), 579-581.
- Rowe, B., Ward, L. R., & Threlfall, E. J. (1997). Multidrug-resistant *Salmonella typhi*: a worldwide epidemic. *Clinical Infectious Diseases*, 24(Suppl 1), S106-S109.
- Saha, S. K., Baqui, A. H., Hanif, M., Darmstadt, G. L., Ruhulamin, M., & Nagatake, T. (2001). Typhoid fever in Bangladesh: Implications for vaccination policy. *Pediatric Infectious Disease Journal*, 20(5), 521-524.
- Saha, S. K., Talukder, S. Y., Islam, M., & Saha, S. (1999). A highly ceftriaxone-resistant *Salmonella typhi* in Bangladesh. *Pediatric Infectious Disease Journal*, 18(4), 387-388.
- Sur, D., Ali, M., von Seidlein, L., Manna, B., Deen, J. L., & Clemens, J. D. (2007). Comparative immunogenicity of two *Salmonella enterica* serovar Typhi vaccines in children aged 2 to 5 years in Kolkata, India. *Clinical and Vaccine Immunology*, 14(7), 888-893.
- Wain, J., Bay, P. V., Vinh, H., Duong, N. M., Diep, T. S., Walsh, A. L., ... & White, N. J. (1999). Quantitation of bacteria in bone marrow from patients with typhoid fever: relationship between counts and clinical features. *Journal of Clinical Microbiology*, 37(5), 1571-1576.
- World Health Organization. (2007). Typhoid fever. Retrieved from WHO.
- Tasnim, T., Tarafder, S., Alam, F., Sattar, H., & Mostofa, K. S. (2018). Pre-Extensively Drug Resistant Tuberculosis (Pre-XDR-TB) among Pulmonary Multidrug Resistant Tuberculosis (MDR-TB) Patients in Bangladesh. *Journal of Tuberculosis Research*, 6, 199-206. <https://doi.org/10.4236/jtr.2018.63018>
- Walid, E., Abdelhalim, M. H., Wael, F. E. T., & Asmaa, S. (2017). Extremely Drug Resistant *Salmonella* in Broiler Production Chain in Egypt. *Life Science Journal*, 14, 81-87.
- Nair, V. T. D., Venkitanarayanan, K., & Kollanoo, J. A. (2018). Antibiotic-Resistant *Salmonella* in the Food Supply and the Potential Role of Antibiotic Alternatives for Control. *Foods*, 7, Article No. 167. <https://doi.org/10.3390/foods7100167>